| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.cian.co | |
| Market Cap | 44.37 Cr. | |
| Enterprise Value(EV) | 112.38 Cr. | 2021-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.02 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 835.55 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 28.41 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 22.21 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 0.80 | Calculated using Price: 17.75 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 2.50 Cr. | 24,995,764 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
The Company was originally incorporated as ‘Cian Healthcare Private Limited’ at Pune, Maharashtra as a private limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated January 07, 2003 issued by Registrar of Companies, Pune, Maharashtra. Subsequently, the Company was converted into a public limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on November 19, 2018 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Pune, Maharashtra dated November 30, 2018 and name of the Company was changed to Cian Healthcare Limited. The Company is a WHO-GMP & ISO -9001:2015 certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products. The Company has a full-fledged F&D and regulatory department. The Company complies with the standard manufacturing practices as laid down by the World Health Organization and is also certified by the Food and Drug Control Administration. Business area of the Company: The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky’s. Major Events and Milestones:
Awards, Achievements and Accolades:
|
||
Company Profile
The Company was originally incorporated as ‘Cian Healthcare Private Limited’ at Pune, Maharashtra as a private limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated January 07, 2003 issued by Registrar of Companies, Pune, Maharashtra. Subsequently, the Company was converted into a public limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on November 19, 2018 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Pune, Maharashtra dated November 30, 2018 and name of the Company was changed to Cian Healthcare Limited.
The Company is a WHO-GMP & ISO -9001:2015 certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products. The Company has a full-fledged F&D and regulatory department. The Company complies with the standard manufacturing practices as laid down by the World Health Organization and is also certified by the Food and Drug Control Administration.
Business area of the Company:
The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky’s.
Major Events and Milestones:
Awards, Achievements and Accolades:
| 1 Day |
|
|
| 1 Week |
|
-6.58% |
| 1 Month |
|
-17.44% |
| 3 Month |
|
-12.78% |
| 6 Month |
|
+1.14% |
| 1 Year |
|
+7.90% |
| 2 Year |
|
+11.99% |
| 5 Year |
|
|
| 10 Year |
|
| 2 years | 2020-03 | 2021-03 | |
| Return on Equity (%) | -7.54 | 0.10 | |
| Return on Capital Employed (%) | 3.00 | 6.99 | |
| Return on Assets (%) | -2.42 | 0.03 |
| Particulars | 2 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 58 | 58 | |
| Non Curr. Liab. | 50 | 41 | |
| Curr. Liab. | 48 | 58 | |
| Minority Int. | |||
| Equity & Liab. | 157 | 157 | |
| Non Curr. Assets | 94 | 88 | |
| Curr. Assets | 54 | 63 | |
| Misc. Exp. not W/O | 8 | 5 | |
| Total Assets | 157 | 157 |
| Particulars | 2 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 57 | 74 | |
| Other Income | 1 | 0 | |
| Total Income | 58 | 74 | |
| Total Expenditure | -50 | -62 | |
| PBIDT | 8 | 12 | |
| Interest | -7 | -8 | |
| Depreciation | -4 | -3 | |
| Taxation | 0 | -1 | |
| Exceptional Items | 0 | 0 | |
| PAT | -4 | 0 | |
| Minority Interest | |||
| Share Associate | |||
| Other Related Items | |||
| Consolidated Net Profit | -4 | 0 | |
| Adjusted EPS | -2 | 0 |
| Particulars | 2 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -7 | 6 | |
| Cash Fr. Inv. | -27 | 3 | |
| Cash Fr. Finan. | 36 | -10 | |
| Net Change | 1 | -1 | |
| Cash & Cash Eqvt | 3 | 2 |
|
Sat, 30 Apr 2022
In Compliance Under Regulation 40(9) & (10) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 Regarding Submission Of The Certificate Of Compliance Report Issued By DSM & ASSOCIATES Company Secretaries For The Year Ended On 31St March 2022. In Compliance Under Regulation 40(9) & (10) of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 regarding submission of the Certificate of Compliance Report issued by DSM & ASSOCIATES Company Secretaries for the Year ended on 31st March 2022. |
||||||||||||||
|
Fri, 22 Apr 2022
Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Financial Year Ended 31St March 2022. Submission of Compliance Certificate under Regulation 7(3) of the SEBI (LODR) Regulations 2015 for the Half Year/Year ended on 31st March 2022. |
||||||||||||||
|
Wed, 20 Apr 2022
Statement Of Investor Complaints For The Quarter Ended March 2022
|
| Wed, 18 May 2022 |
High Delivery Percentage
|
Close Crossing Last Week Low
|
Opening at High
|
Closing Below Previous Low
|
High Decrease 1 Month
|
Equities
M.F.
Sectors